mif

MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.13460-73-86-5

MIF098, a macrophage migration inhibitory factor (MIF) antagonist, inhibits pulmonary hypertension associated with SLE and the proliferation and migration of pulmonary arterial smooth muscle cells (PASMC). MIF098 may also be used to study idiopathic pulmonary hypertension.

(±)-CPSI-1306 (2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one) is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

ISO-1 (MIF Antagonist) is an inhibitor of the dopachrome tautomerase activity, blocks the activation of NF-κB and TNF-α secretion from LPS-treated macrophages.

4-IPP (4-Iodo-6-phenylpyrimidine) is an irreversible inhibitor of macrophage migration inhibitory factor (MIF).

MIF-IN-1 (compound 14) is a potent inhibitor of macrophage migration inhibitory factor (MIF) with a pIC50 of 6.87, targeting a proinflammatory cytokine linked to various diseases, including neurodegenerative disorders [1].

MIF-IN-5 (compound 1d) is a potent, reversible competitive inhibitor of macrophage migration inhibitory factor (MIF), with an IC₅₀ of 4.8 μM and a Ki of 3.3 μM [1].

MIF-IN-6 (compound 2d) is an effective inhibitor of macrophage migration inhibitory factor (MIF), with an IC50 of 1.4 μM and a Ki value of 0.96 μM. It effectively reduces MIF-induced ERK phosphorylation and impedes A549 cell proliferation [1].

MIF-IN-3 is an inhibitor of migration inhibitory factor (MIF), which can be used in the study of immunoinflammation-related diseases.

MIF-IN-4 hydrochloride is a potent inhibitor of macrophage mobility inhibitory factor (MIF) with pIC50 values ranging from 5.01-6. Where MIF was originally discovered as a cytokine in the process of inhibiting macrophage migration.

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

Epoxyazadiradione is an extract from Neem (Azadirachta indica) plant and may induce mitochondrial apoptosis and inhibition of NF-kB in human cervical cancer cells.

Boc-MIF-1-Am (compound 2) acts as a human dopamine D2 receptor enhancer with an EC50 value of 17.82 nM and is a bioconjugate of melanostatin (MIF-1) and amantadine. At a concentration of 200 μM, Boc-MIF-1-Am exhibits slight neurotoxicity in SH-SY5Y cells.

MIF-1 TFA (Melanostatin), an intrinsic brain peptide, serves as a powerful allosteric modulator of the dopamine receptor. It plays a crucial role in regulating melanin production and modifies the analgesic efficacy by inhibiting the opioid receptor's effects. Significantly, MIF-1 TFA can cross the blood-brain barrier (BBB) directly, facilitating its access from the bloodstream to the central nervous system (CNS) [1] [2] [3].

Tyr-W-MIF-1, an opioid tetrapeptide, exhibits both opiate and antiopiate activities, and has been demonstrated to induce analgesia [1] [2] [5].

MIF2-IN-1 (compound 5d) is a potent MIF2 tautomerase inhibitor (IC50: 1.0 μM) that inhibits the proliferation of non-small cell lung cancer cells by arresting the cell cycle through the MAPK pathway, with potential applications in cancer disease studies.

BTZO-1 is an antioxidant response element (ARE) activator with cardioprotective activity.

The MIF Antagonist IV, RDR 03785 controls the biological activity of MIF. This small molecule/inhibitor is primarily used for Cell Structure applications.

HTS05585 (Compound Hit-1) is a selective inhibitor of macrophage migration inhibitory factor (MIF) with a Kd value of 0.29 μM determined by microscale thermophoresis (MST) and confirmed through isothermal titration calorimetry (ITC) at 0.32 μM. It suppresses the release of pro-inflammatory factors (TNF-α, IL-6, IL-1β) in macrophages induced by LPS, making it a promising candidate for the study of inflammatory diseases such as sepsis.

4-CPPC is an inhibitor of macrophage migration inhibitory factor-2 (MIF-2; IC50= 27 μM).1It is selective for MIF-2 over MIF-1 (IC50= 450 μM). It inhibits MIF-2, but not MIF-1, binding to CD74in vitrowhen used at a concentration of 10 μM. 4-CPPC (5, 10, and 25 μM) inhibits MIF-2-induced ERK1/2 phosphorylation in primary human skin fibroblasts. 1.Tilstam, P.V., Pantouris, G., Corman, M., et al.A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activityJ. Biol. Chem.294(49)18522-18531(2019)

Iguratimod (T614) is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.

MKA031 (compound 6y) is a non-competitive inhibitor of macrophage migration inhibitory factor (MIF) with an IC50 of 1.7 μM. It disrupts the MIF-aryl hydrocarbon receptor interacting protein (AIF) interaction, impedes MIF nuclear translocation, and mitigates N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced cell death. MKA031 is applicable in research on chronic hepatitis C virus infection [1].

Carebastine, the active metabolite of Ebastine, is an antagonist of the histamine H1 receptor.

Mitomycin A is a cytotoxic antibiotic derived from Streptomyces sp. with anticancer activity and antitumor activity.Mitomycin A is used in the study of solid cancers.